Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CUE 
Cue Biopharma (CUE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: CUE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.88% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 52.76M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 4 | Beta 1.42 | 52 Weeks Range 0.45 - 1.99 | Updated Date 07/7/2025 |
52 Weeks Range 0.45 - 1.99 | Updated Date 07/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.64 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2921.38% |
Management Effectiveness
Return on Assets (TTM) -67.62% | Return on Equity (TTM) -221.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 46372237 | Price to Sales(TTM) 6.6 |
Enterprise Value 46372237 | Price to Sales(TTM) 6.6 | ||
Enterprise Value to Revenue 5.8 | Enterprise Value to EBITDA -1.76 | Shares Outstanding 75349904 | Shares Floating 75083896 |
Shares Outstanding 75349904 | Shares Floating 75083896 | ||
Percent Insiders 0.35 | Percent Institutions 15.19 |
Upturn AI SWOT
Cue Biopharma
Company Overview
History and Background
Cue Biopharma, founded in 2011, is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable biologics to selectively engage and modulate the human immune system directly within the body to fight cancer and autoimmune diseases. Their Immuno-STAT (Selective Targeting and Activation of T cells) platform is designed to harness the body's natural defenses.
Core Business Areas
- Immuno-STAT Platform: Development of biologics using the Immuno-STAT platform to selectively activate and modulate T cells for cancer and autoimmune diseases. Their lead product candidate is CUE-101.
Leadership and Structure
The leadership team consists of Ayacut Gokirmak (CEO), Kerri-Ann Millar (Chief Financial Officer), and other experienced executives in the biopharmaceutical industry. The company has a board of directors that oversees its strategic direction.
Top Products and Market Share
Key Offerings
- CUE-101: CUE-101 is Cue Biopharma's lead drug candidate, an Immuno-STAT biologic designed to selectively activate and expand tumor-specific CD8+ T cells to target HPV16-driven cancers. It is currently in clinical trials. Market share data and specific revenue figures are not publicly available as it is still in the development phase. Competitors include companies developing immunotherapies for HPV-driven cancers, such as Merck (Keytruda) and Bristol Myers Squibb (Opdivo), although their mechanisms are different.
- CUE-102 & CUE-103: CUE-102 & CUE-103 are earlier stage Immuno-STAT biologics targeting other cancers. No market share or revenue data is available as they are in pre-clinical and early clinical development. Competitors are similar to those for CUE-101.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investment in immunotherapy and targeted therapies. The cancer immunotherapy market is experiencing strong growth driven by advances in understanding the immune system and the development of novel therapeutic approaches.
Positioning
Cue Biopharma is positioned as an innovator in the field of T cell modulation. Its Immuno-STAT platform offers a unique approach compared to traditional checkpoint inhibitors and cell therapies. The competitive advantage lies in selective T cell activation within the body, aiming for improved efficacy and reduced toxicity.
Total Addressable Market (TAM)
The TAM for cancer immunotherapy is estimated to be in the tens of billions of dollars annually. Cue Biopharma is targeting specific cancers, such as HPV-driven cancers, which represent a significant portion of the overall TAM. Their position is in the early stages of commercialization and gaining market share would heavily depend on clinical trial success and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel Immuno-STAT platform
- Targeted T cell activation
- Potential for improved efficacy and safety
- Strong scientific team
Weaknesses
- Limited clinical data
- Early stage of development
- Reliance on clinical trial success
- High cash burn rate
Opportunities
- Expanding clinical trials to new indications
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results driving market adoption
- Advancements in understanding of the immune system
Threats
- Clinical trial failures
- Competition from established immunotherapy players
- Regulatory hurdles
- Financing challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- GILD
Competitive Landscape
Cue Biopharma's competitive advantage lies in its novel Immuno-STAT platform, offering targeted T cell activation. However, it faces significant competition from established players with approved immunotherapies and larger resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in preclinical and clinical advancements, which have been slow with the amount of funding available
Future Projections: Future projections depend on clinical trial outcomes, regulatory approvals, and market adoption. Analyst estimates are subject to change and require financial data subscriptions.
Recent Initiatives: Recent initiatives include advancing CUE-101 through clinical trials and expanding the pipeline with new Immuno-STAT candidates.
Summary
Cue Biopharma is an early-stage company with a promising Immuno-STAT platform, but faces significant challenges. Clinical trial successes are vital for its growth trajectory. Competition from established players and financial constraints are key considerations. Positive clinical data and strategic partnerships could improve its prospects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (subscription required)
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on independent research and professional consultation. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cue Biopharma
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2018-01-02 | CEO, Interim Principal Financial and Accounting Officer & Director Mr. Daniel R. Passeri J.D., M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 41 | Website https://www.cuebiopharma.com |
Full time employees 41 | Website https://www.cuebiopharma.com | ||
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.